# The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

> **NCT06117137** · PHASE3 · COMPLETED · sponsor: **Sohag University** · enrollment: 150 (actual)

## Conditions studied

- Fatty Liver, Nonalcoholic

## Interventions

- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT06117137
- **Lead sponsor:** Sohag University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-15
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-04-03
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06117137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06117137, "The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06117137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*